Clinical Trials Logo

Testicular Germ Cell Tumor clinical trials

View clinical trials related to Testicular Germ Cell Tumor.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06276491 Recruiting - Ovarian Cancer Clinical Trials

Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors

Start date: April 4, 2024
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.

NCT ID: NCT06133699 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors

PITERLAND
Start date: November 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of sentinel lymph node biopsy in stage AI-IIA germ cell tumors (seminoma/nonseminoma). The main questions it aims to answer are: - To evaluate relapse-free survival during the first two years after SLNB. - To estimate the percentage of patients who did not require adjuvant treatment after primary endoscopic SLNB. - Determine the microRNA expression profile in blood plasma, evaluate miRNAs as a potential prognostic and predictive factor in patients with testicular germ cell tumors. - Assess the correlation between computed tomography and positive lymph nodes on examination. Participants will undergo: - surgical treatment including orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye. - 24 hours before the procedure, a radiopharmaceutical (RP) is injected into the spermatic cord, followed by SPECT to determine the regional sentinel lymph node(s). - The level of microRNA will be examined before surgery and 10 days after surgery.

NCT ID: NCT05670938 Recruiting - Quality of Life Clinical Trials

Follow-up After Surgery for Testicular Cancer

FUTURE-testis
Start date: November 30, 2022
Phase:
Study type: Observational

The currently developed implementation study aims to evaluate if a patient-led home-based follow-up approach is successful, improves quality of life, reduces anxiety and lessens fear of cancer recurrence during the years after treatment of certain types of testicular cancer.

NCT ID: NCT05238883 Recruiting - Gastric Cancer Clinical Trials

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Start date: March 10, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200301 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200301 as a single agent or combination therapy is determined. During the expansion part, participants will take the dose of HFB200301 as a monotherapy or in combination with tislelizumab that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

NCT ID: NCT03980587 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Exploratory Study of Molecular Characterization in Patients With Metastatic Germ Cell Tumours Refractory/Resistant to Platinum Treatment

EMIT
Start date: August 2019
Phase:
Study type: Observational

1. To establish whether circulating tumour DNA is detectable in the plasma of patients with platinum refractory/resistant Germ Cell Tumours 2. If ctDNA is detectable, perform exploratory analyses to: 1. Describe the molecular aberrations in plasma from metastatic GCTs with platinum refractory/resistant disease 2. Describe aberrations detected in sequential detected in sequential samples form the same individual patient and evaluate whether there are hyposthesis-generating changes that temporarily associate with clinical resistance.

NCT ID: NCT01172912 Recruiting - Clinical trials for Brain and Central Nervous System Tumors

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy

Start date: October 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. An autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. PURPOSE: This phase II trial is studying the side effects of giving high-dose chemotherapy together with stem cell transplant and to see how well it works in treating patients with metastatic germ cell tumors that have not responded to first-line therapy.

NCT ID: NCT01087268 Recruiting - Prostate Cancer Clinical Trials

Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer

Start date: January 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer. It is not yet known whether high-pressure oxygen is effective in treating adverse effects caused by radiation therapy. PURPOSE: This randomized phase III trial is studying hyperbaric oxygen therapy to see how well it works in treating long-term gastrointestinal adverse effects caused by radiation therapy in patients with pelvic cancer.

NCT ID: NCT00589537 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle

Start date: March 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Imaging procedures, such as MRI and CT scan, may find recurrent cancer. It is not yet known which MRI or CT scan schedule is more effective in finding recurrent cancer. PURPOSE: This randomized phase III trial is comparing four different MRI and CT scan schedules in patients with stage I seminoma of the testicle.

NCT ID: NCT00553371 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer

Start date: April 2006
Phase: N/A
Study type: Observational

RATIONALE: Learning about long-term effects in patients with testicular cancer may help doctors plan better treatment and follow-up care. PURPOSE: This clinical trial is using CT scans to follow patients who have been treated for metastatic testicular cancer.

NCT ID: NCT00551122 Recruiting - Ovarian Cancer Clinical Trials

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

GemTIP
Start date: November 2006
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when given together with paclitaxel, ifosfamide, and cisplatin, and to see how well they work in treating patients with progressive or relapsed metastatic germ cell tumors.